Financing included participation from new and existing investors Pro forma cash and cash equivalents expected to fund current operating plan into 2027 enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead …
Trending at Lumira Ventures
Lumira Ventures Portfolio Company enGene (Nasdaq: ENGN) Debuts as Publicly Traded Genetic Medicines Company
CAD$191 million gross proceeds from the transaction to support the advancement of the clinical program and pipeline expansion Pivotal clinical trial for lead program EG-70 targeting BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) currently enrolling patients Lumira Ventures portfolio company enGene …
enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer
enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, …
enGene Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
enGene Inc., a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced positive results from its LEGEND study, a first-in-human Phase 1/2 clinical trial of EG-70 for the treatment …
Lumira Portfolio Company, enGene, Announces First-in-Human Dosing of EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer in Phase 1/2 Clinical Trial
BOSTON and MONTRÉAL, May 27, 2021: enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced the dosing of the first patient in the LEGEND study, a first-in-human Phase 1/2 …
enGene Receives Fast Track Designation for EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer
enGene Inc., A biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to enGene for EG-70, the company’s lead …
enGene Receives Funding Through Cystic Fibrosis Foundation’s Path to a Cure for the Discovery of Novel Gene Therapies to Treat Cystic Fibrosis
OSTON and MONTRÉAL, Oct. 29, 2020 /PRNewswire/ -enGene Inc., a biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, announced today an award from the Cystic Fibrosis Foundation for the discovery of genetic medicines to treat patients …
enGene Expands Senior Management Team
BOSTON and MONTRÉAL /PRNewswire/ – enGene Inc., the biotechnology company developing rationally designed gene therapies targeted to mucosal tissues through its proprietary non-viral vector DDX® platform, today announced the appointments of Sharon Tan as Vice President and Head of Program Management, and Lance …
enGene Appoints José M. Lora, Ph.D. as Chief Scientific Officer
MONTRÉAL and BOSTON, May 29, 2019 — enGene Inc., the high growth biotechnology company developing the Gene Pill™ – a robust, proprietary non-viral vector platform to deliver gene therapies via oral administration – today announced the appointment of José M. Lora, Ph.D., as Chief Scientific …
enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President
MONTRÉAL and BOSTON, /CNW/ – enGene Inc., a biotechnology company developing novel non-viral vector gene therapies to provide oral delivery of a wide range of protein drugs, including the Gene Pill™ , today announced the appointment of Jason D. Hanson as President, Chief Executive Officer and …
enGene announces appointment of Theresa Podrebarac, MD, as Chief Medical Officer
MONTREAL, May 1, 2017 /CNW/ – enGene Inc. announced today that Theresa Podrebarac, MD, has joined the company as Chief Medical Officer. In her new position, Dr. Podrebarac will be responsible for designing and executing clinical development plan for enGene’s …
enGene’s mucosal gene delivery platform is successful in targeting PD-L1 expression in the gut, demonstrating effective treatment of colitis and GvHD in preclinical models
• enGene’s proprietary PD-L1 gene therapy is being developed as potential novel therapy for acute GvHD • Late-breaking abstract on preclinical data from PD-L1 program will be presented at Digestive Disease Week (DDW) 2017 in Chicago MONTREAL, April 28, 2017 …
The Top 5 Canadian Biotech CEOs who elevate their companies
BY COMPILED BY SHAWN LAWRENCE • MARCH 11, 2016 • BUSINESS FOCUS, FEATURE SLIDER, FEATURED-SLIDES-HOME, MANAGEMENT UPDATES • COMMENTS (0) • 798 The-Top-5-Canadian-Biotech-CEOs-They are industry leaders that capture the attention and confidence of the Canadian biotech investment community. They represent …
Takeda and enGene Establish Strategic Alliance to Develop Novel Therapeutics for Gastrointestinal Diseases
OSAKA, Japan & MONTREAL–(BUSINESS WIRE)–Takeda Pharmaceutical Company Ltd. (TOKYO:4502) and enGene, Inc. today announced a strategic alliance to discover, develop and commercialize novel therapies for specialty gastrointestinal (GI) diseases using enGene’s “Gene Pill” gene delivery platform. The strategic alliance will …
enGene Announces Strategic Collaboration with Johnson & Johnson Innovation to Develop Novel Gene Delivery Products for Inflammatory Bowel Disease
MONTREAL, CANADA October 14, 2015 – enGene, Inc. a gene therapy company focused on development of therapeutics using its proprietary “Gene Pill” and enema gene delivery platform, today announced that it has entered into a definitive agreement with Janssen Biotech, Inc., …
- Page 1 of 2
- 1
- 2